Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.…
Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock?
Alzamend Neuro (NASDAQ: ALZN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 0.7758 USD on 20 November 2026, down 67.4% over 52 weeks. Its 52-week range is 0.7550 USD to 2.560 USD: the price is 69.7% below the high and 2.8% above the low.
Its market capitalisation is 3.74M USD.
Alzamend Neuro reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 7.59M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.